Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Divestments (2017 - 2020)

Aptevo Therapeutics' Divestments history spans 3 years, with the latest figure at $28.1 million for Q1 2020.

  • For Q1 2020, Divestments changed N/A year-over-year to $28.1 million; the TTM value through Dec 2020 reached $28.1 million, up 15182.61%, while the annual FY2020 figure was $28.1 million, 561.65% up from the prior year.
  • Divestments for Q1 2020 was $28.1 million at Aptevo Therapeutics, up from $65000.0 in the prior quarter.
  • Across five years, Divestments topped out at $28.1 million in Q1 2020 and bottomed at -$714000.0 in Q4 2017.
  • The 3-year median for Divestments is $65000.0 (2018), against an average of $5.5 million.